Sign in

You're signed outSign in or to get full access.

Shane Storey

Research Analyst at Canaccord Genuity

Shane Storey is an Equity Analyst at Canaccord Genuity, specializing in the Australian healthcare sector including pharmaceuticals, biotechnology, medical devices, and healthcare services. He covers companies such as Telix Pharmaceuticals, Orthocell, Impedimed, ResMed, Hexima, Silk Laser Australia, Next Science, Capitol Health, and Pacific Smiles Group, with a strong performance track record as a 4-star analyst on TipRanks featuring a 51-52% success rate, average return of 8.1%, and a top call on Telix yielding +174.7% over one year. Storey began his career with roles in drug development, R&D project management, and venture capital before joining Wilsons Corporate Finance as Director of Research - Equity in 2007, later moving to Pinnacle Investment Management and Canaccord Genuity around 2025. He holds a doctorate from University College London, postgraduate qualifications in molecular biology, engineering, and finance from Macquarie Graduate School of Management, and an undergraduate degree from the University of Queensland.

Shane Storey's questions to Telix Pharmaceuticals (TLX) leadership

Question · H2 2025

Shane Storey asked about the customer channel strategy for Pyxclara, noting its difference from the PSMA urology presence, and how the Varian relationship might evolve in this context.

Answer

Kevin Richardson, CEO of the Precision Medicine Business, described a 'ninja team' focused on neurologists for referrals, leveraging existing nuclear medicine site relationships. He highlighted that this approach provides access to orphan drug technologies and competitive advantage, even in sites not using Illuccix or Gozellix.

Ask follow-up questions

Fintool

Fintool can predict Telix Pharmaceuticals logo TLX's earnings beat/miss a week before the call

Question · H2 2025

Shane Storey asked for a description of the customer channel for Pixclara, noting its difference from the PSMA urology presence, and whether it represents a first example of how the Varian relationship might evolve.

Answer

Kevin Richardson, CEO of the Precision Medicine Business, explained that a specialized 'ninja team' focuses on neurologists for Pixclara referrals, leveraging existing nuclear medicine relationships for scanning. This strategy provides competitive access for orphan drug technologies, with the Varian relationship primarily focused on PSMA. CEO Christian Behrenbruch added no further comments.

Ask follow-up questions

Fintool

Fintool can write a report on Telix Pharmaceuticals logo TLX's next earnings in your company's style and formatting